Named Bioactive Compounds · Compound
Psoralidin (Coumestan)
Moderate Evidencephenolic1 PubMed Study
Hermetica Superfood Encyclopedia
Psoralidin is a coumestan compound found in Psoralea corylifolia that demonstrates selective estrogen receptor modulating properties. This bioactive compound inhibits bone resorption and protein tyrosine phosphatase 1B, suggesting potential benefits for bone health and metabolic regulation.
Psoralidin is a prenylated coumestan derivative extracted from Psoralea corylifolia L. (Leguminosae), a plant widely distributed across Asia, India, and Europe. It can be extracted from plant sources or synthesized in laboratory conditions through condensation, intramolecular cyclization, and cross metathesis reactions, yielding approximately 73%.
No human clinical trials, randomized controlled trials (RCTs), or meta-analyses are available for psoralidin. All evidence comes from preclinical studies including in vitro experiments and animal models, with no PubMed PMIDs for human trials provided in the research.
No clinically studied dosage ranges for human use are available. The only concentration mentioned is 10 μM used in in vitro estrogen receptor activation studies. Nanoencapsulated formulations show 339.02% improved bioavailability compared to simple suspensions in animal models. Consult a healthcare provider before starting any new supplement.
Psoralidin is a naturally occurring coumestan (a subclass of isoflavonoids) with the molecular formula C₂₀H₁₆O₅ and a molecular weight of ~336.34 g/mol. It is not a nutrient per se but a bioactive phytochemical found primarily in the seeds and fruits of Psoralea corylifolia (Cullen corifolium, commonly known as Babchi). Key biochemical and compositional details include: • Chemical class: Coumestan (prenylated coumestan derivative), structurally related to isoflavones and sharing the benzofuran-coumarin fused ring system. • Typical concentration in source material: Found at approximately 0.1–1.5% (w/w) in dried Psoralea corylifolia seeds, depending on extraction method and plant origin; often co-occurs with other bioactive prenylated compounds such as bakuchiol (~1–5%), psoralen (~0.5–2%), and isopsoralen. • Bioactive functional groups: Contains a prenyl (3-methylbut-2-enyl) side chain at C-2 position and hydroxyl groups critical for its biological activity, including protein tyrosine phosphatase 1B (PTP1B) inhibition (IC₅₀ ~3.5–9.2 µM in vitro) and estrogen receptor binding. • Solubility and bioavailability: Poorly water-soluble (lipophilic compound, LogP ~4.2); oral bioavailability is estimated to be low due to limited aqueous solubility, rapid Phase I/II hepatic metabolism (glucuronidation and sulfation), and potential P-glycoprotein efflux. Co-administration with lipid-based carriers or piperine may enhance absorption. • No appreciable macronutrient contribution (protein, carbohydrate, fat, fiber): As a secondary plant metabolite consumed in microgram-to-low-milligram quantities (typical supplement or traditional medicine doses of crude Psoralea extract deliver roughly 1–10 mg psoralidin), it provides no caloric or macronutrient value. • No significant vitamin or mineral content attributable to psoralidin itself; however, whole Psoralea corylifolia seed preparations contain trace minerals (calcium, phosphorus, iron) and other phytochemicals. • Key co-occurring bioactives in source plant that may exhibit synergistic effects: bakuchiol (meroterpene, antioxidant), psoralen and isopsoralen (furanocoumarins, photosensitizing), corylifol A, and neobavaisoflavone. • Stability notes: Sensitive to UV light and alkaline conditions; relatively stable under acidic and neutral pH in dry storage.
Psoralidin functions as a selective estrogen receptor modulator (SERM), binding to estrogen receptors to inhibit osteoclast-mediated bone resorption. The compound specifically inhibits protein tyrosine phosphatase 1B (PTP1B), a negative regulator of insulin signaling pathways. Additionally, psoralidin demonstrates anti-proliferative effects through cell cycle arrest and apoptosis induction in cancer cell lines.
Current evidence for psoralidin comes primarily from in vitro and animal studies, with limited human clinical data. Ovariectomized rat studies showed significant reduction in bone loss markers at 50-100 mg/kg doses over 12 weeks. In vitro studies demonstrate PTP1B inhibition with IC50 values ranging from 15-25 μM. Anti-cancer activity has been observed in gastric and colon cancer cell lines, but human efficacy trials are lacking.
Safety data for psoralidin supplementation in humans is limited due to lack of clinical trials. As a phytoestrogenic compound, psoralidin may interact with hormone replacement therapy and estrogen-sensitive medications. Potential concerns include interactions with anticoagulant drugs due to coumarin-like structure. Pregnant and breastfeeding women should avoid psoralidin supplements due to unknown safety profile and estrogenic activity.
